14 May

Why Insys Therapeutics Fell More than 70% Yesterday

WRITTEN BY Margaret Patrick

Liquidity position

In its first-quarter earnings press release, which it published on May 10, Insys Therapeutics (INSY) highlighted the possibility of its being unable to continue as a going concern. While the company reported cash and cash equivalents worth $87.6 million on its balance sheet at the end of the first quarter, it estimated that the liability arising from the settlement of ongoing litigations would exceed $240.3 million.

Why Insys Therapeutics Fell More than 70% Yesterday

Insys Therapeutics’ revenue fell 68.2% YoY (year-over-year) to $7.63 million in the first quarter of 2019. However, its legal expenses associated with the US Department of Justice’s civil and criminal investigation and other litigations rose 148.30% YoY to $25.67 million. Potential contingent losses associated with litigations and settlements jumped 9,881.49% YoY to reach $73.86 million in the first quarter.

According to its first-quarter earnings press release, Insys Therapeutics has been considering strategic alternatives such as the sale or licensing of its portfolio of opioid-related assets to meet its operating cash flow requirements. However, in the event that it fails to implement the strategy or complete the settlement with the Department of Justice, Insys Therapeutics has stated that it could have to file for relief under Chapter 11 of the United States Bankruptcy Code.

Share price movements

In response to this announcement, Insys Therapeutics stock fell 73.61% and closed at $0.95 on May 13, 71.64% lower than its 52-week low of $3.35 and 91.84% lower than its 52-week high of $11.65. The company’s market cap is $79.94 million. Since its market cap is lower than $300 million, it’s a micro-cap stock and can prove to be a riskier investment than the broader market.

Insys Therapeutics’ price-to-sales and price-to-cash ratios are 0.97x and 0.84x, respectively. The company’s 14-day relative strength index is currently 12.99. Its number of outstanding shares is 84.14 million, while its short float ratio is 42.73%.

Latest articles

With over 38,000 restaurants, McDonald's doesn’t make any of its products. Instead, it contracts with suppliers to meet its massive requirements.

In Q3, T-Mobile’s (TMUS) strong momentum continued. The telecom giant gained postpaid phone customers and reported strong earnings.

Energy Transfer stock (ET) has been under pressure due to a weak earnings season from MLPs, but its fundamentals are stronger than ever.

Former HBO CEO Richard Plepler is in "advanced talks" over a deal with Apple TV+ (AAPL), the Wall Street Journal reported on Tuesday.

At 11:46 AM ET, US crude oil prices were up 0.7% from the last trading session. The EIA plans to release its inventory report tomorrow.

Footwear and apparel giant Nike (NKE) has decided to stop selling its products on Amazon (AMZN), ending a program that's run since 2017.